Comparative Pharmacology
Head-to-head clinical analysis: XYLOCAINE versus XYLOCAINE 4 PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XYLOCAINE versus XYLOCAINE 4 PRESERVATIVE FREE.
XYLOCAINE vs XYLOCAINE 4% PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx through voltage-gated sodium channels, thereby blocking the initiation and propagation of action potentials, resulting in local anesthesia.
1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 mL.
Maximum 4.5 mg/kg (not to exceed 300 mg) via subcutaneous infiltration, epidural, or nerve block; repeat dosing after 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in adults, prolonged to 2-3 hours in patients with hepatic impairment, and may exceed 5 hours in neonates or patients with heart failure.
Terminal elimination half-life: ~1.5–2 hours (adults). Prolonged in hepatic impairment, congestive heart failure, or neonates.
Hepatic metabolism (primarily by CYP1A2 and CYP3A4) to metabolites, mainly monoethylglycinexylidide (MEGX) and glycinexylidide (GX); less than 10% excreted unchanged in urine. Renal excretion of metabolites: MEGX (70-80%) and GX (10-20%). Biliary/fecal elimination is minimal.
Renal: ~90% as metabolites (mostly 4-hydroxy-2,6-xylidine and conjugates); <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic